Renal Dysplasia

Renal dysplasia is a congenital or hereditary developmental disorder of the kidney characterized by abnormal differentiation and organization of renal tissue, leading to the presence of primitive structures such as fetal glomeruli, immature tubules, and metaplastic cartilage or bone. It results from aberrant nephrogenesis, which in dogs and cats typically ceases around 2-3 weeks postnatally. The condition may be unilateral or bilateral, and when bilateral, it often progresses to chronic kidney disease (CKD) at a young age. Renal dysplasia is a common cause of juvenile-onset renal failure in certain breeds, and its severity varies from subclinical to rapidly progressive end-stage renal disease.

The exact etiology of renal dysplasia is often unknown but is believed to be primarily genetic, with a hereditary basis in many breeds. In dogs, an autosomal recessive mode of inheritance has been suggested for some breeds, such as the Shih Tzu, Lhasa Apso, and Golden Retriever. In cats, a hereditary form has been reported in the Persian breed. Teratogenic insults during in utero development, such as exposure to certain drugs (e.g., corticosteroids, angiotensin-converting enzyme inhibitors), viral infections (e.g., feline panleukopenia virus), or toxins, may also disrupt nephrogenesis. However, in most cases, a specific cause is not identified. The condition is congenital, meaning it is present at birth, but clinical signs may not manifest until months to years later as renal function declines.

Renal dysplasia is most commonly diagnosed in young dogs and cats, typically under 3-4 years of age, but can be identified incidentally in older animals. Breed predispositions in dogs include the Shih Tzu, Lhasa Apso, Golden Retriever, Standard Poodle, Keeshond, Alaskan Malamute, Chow Chow, and Miniature Schnauzer. In cats, the Persian breed is overrepresented. There is no clear sex predilection. The condition is relatively uncommon in the general population but accounts for a significant proportion of juvenile CKD cases. Geographic distribution is worldwide, with no seasonal variation. The prevalence is higher in purebred animals due to genetic transmission, and breeding of affected individuals or carriers should be discouraged.

Renal dysplasia arises from abnormal metanephric differentiation during fetal development. Normally, nephrogenesis proceeds from the inner medulla to the outer cortex, with maturation of glomeruli and tubules. In dysplasia, this process is disrupted, leading to persistent primitive glomeruli (fetal glomeruli) and immature tubules, often surrounded by fibrous tissue. Metaplastic cartilage or bone may form. The abnormal nephrons are nonfunctional or poorly functional, resulting in reduced renal mass and compensatory hypertrophy of remaining normal nephrons. As the animal grows, the functional demand on the kidneys increases, but the dysplastic tissue cannot adapt, leading to progressive glomerulosclerosis, tubulointerstitial fibrosis, and loss of renal function. This culminates in chronic kidney disease with azotemia, impaired urine concentrating ability, and eventual end-stage renal failure. Secondary hyperparathyroidism, systemic hypertension, and anemia may develop as complications.

Intrinsic risk factors include genetic predisposition, with certain breeds having a higher incidence. A family history of renal dysplasia is a significant risk factor. Age is a factor, as clinical signs typically appear in young animals. Extrinsic factors include in utero exposure to teratogens, such as certain drugs (e.g., corticosteroids, ACE inhibitors) or infections (e.g., feline panleukopenia virus). Nutritional factors, such as a high-protein diet in early life, may exacerbate progression of renal damage but are not primary causes. Concurrent conditions that increase renal workload, such as dehydration or urinary tract infections, can accelerate decline. Immunosuppression or chronic inflammation may also contribute to progression.

Clinical signs are often insidious and may not appear until significant renal function is lost. In young animals, common presenting signs include polyuria, polydipsia, poor growth, lethargy, inappetence, and weight loss. As the disease progresses, vomiting, diarrhea, oral ulcers, and uremic breath may occur. Physical examination may reveal small, irregular kidneys on abdominal palpation, pale mucous membranes due to anemia, and signs of dehydration. In advanced stages, systemic hypertension may be detected, and ophthalmic findings such as retinal detachment or hypertensive retinopathy may be present. Some animals may present with signs of renal secondary hyperparathyroidism, including bone pain or pathological fractures. In cases of unilateral dysplasia, the animal may be asymptomatic, and the condition is often an incidental finding.

Differential diagnoses for renal dysplasia include: 1) Juvenile chronic kidney disease due to other congenital anomalies (e.g., renal hypoplasia, renal aplasia, polycystic kidney disease) – these can be differentiated by histopathology and imaging; 2) Acquired chronic kidney disease (e.g., chronic interstitial nephritis, glomerulonephritis) – typically occurs in older animals, but can be differentiated by history and biopsy; 3) Renal amyloidosis – may be suspected with proteinuria and confirmed by biopsy with Congo red staining; 4) Renal neoplasia (e.g., nephroblastoma) – imaging and biopsy are needed; 5) Pyelonephritis – usually associated with fever, bacteriuria, and positive urine culture; 6) Acute kidney injury (e.g., due to toxins or ischemia) – has a more acute onset and may be reversible; 7) Hydronephrosis – due to ureteral obstruction, can be identified by imaging; 8) Renal cysts (e.g., polycystic kidney disease) – seen on ultrasound; 9) End-stage renal disease of any cause – histopathology is required for definitive diagnosis; 10) Diabetes insipidus – presents with polyuria/polydipsia but no azotemia.

The diagnostic approach begins with a thorough history and physical examination, with emphasis on age, breed, and palpation of kidneys. Initial laboratory tests include a complete blood count, serum biochemistry profile, urinalysis, and urine culture. If azotemia and poor urine concentrating ability are present, renal disease is confirmed. Next, abdominal imaging (radiography and ultrasonography) is performed to assess kidney size, shape, and architecture. Renal dysplasia often shows small, irregular kidneys with increased echogenicity and loss of corticomedullary distinction. If the diagnosis remains uncertain, renal biopsy is the gold standard for definitive diagnosis, revealing characteristic histopathological features. Genetic testing may be available for some breeds. In cases of suspected secondary complications, blood pressure measurement and assessment of calcium/phosphate metabolism are recommended.

Hematology may reveal non-regenerative anemia due to decreased erythropoietin production. Serum biochemistry typically shows elevated blood urea nitrogen (BUN) and creatinine, hyperphosphatemia, and metabolic acidosis. Electrolyte abnormalities may include hyperkalemia and hyponatremia in advanced stages. Urinalysis often reveals isosthenuria (urine specific gravity between 1.008 and 1.012), proteinuria, and occasionally casts. The urine protein-to-creatinine ratio (UPC) may be elevated. Blood gas analysis may confirm metabolic acidosis. Biomarkers such as symmetric dimethylarginine (SDMA) are more sensitive than creatinine for early detection of decreased renal function. Parathyroid hormone (PTH) levels may be elevated due to secondary hyperparathyroidism. Serology and PCR for infectious causes (e.g., leptospirosis, feline leukemia virus) may be performed to rule out other etiologies.

Abdominal radiography may show small, irregular kidneys, but this is not specific. Ultrasonography is the most useful imaging modality, revealing small kidneys with increased cortical echogenicity, loss of corticomedullary junction, and possibly cysts or mineralization. Doppler ultrasound can assess renal blood flow. Computed tomography (CT) and magnetic resonance imaging (MRI) are rarely needed but can provide detailed anatomical information, especially for surgical planning in cases of unilateral disease. In advanced cases, renal scintigraphy may be used to assess differential renal function. Imaging is also useful to rule out other congenital anomalies such as hydronephrosis or renal cysts.

Fine needle aspiration (FNA) of the kidney is rarely diagnostic for renal dysplasia, as it may only show nonspecific changes such as tubular epithelial cells or inflammatory cells. Histopathology from a renal biopsy is essential for definitive diagnosis. Characteristic findings include the presence of fetal glomeruli (small, immature glomeruli with cuboidal epithelium), primitive tubules, persistent mesenchyme, and metaplastic cartilage or bone. There is often interstitial fibrosis and tubular atrophy. The lesions are typically diffuse but may be segmental. Special stains such as Masson's trichrome can highlight fibrosis. Immunohistochemistry may be used to assess the expression of developmental markers, but this is primarily for research.

Treatment is primarily supportive and aimed at managing chronic kidney disease. In acute decompensation, intravenous fluid therapy with balanced crystalloids is indicated to correct dehydration and electrolyte imbalances. Long-term management includes a renal-friendly diet (low protein, low phosphorus, omega-3 fatty acids), phosphate binders (e.g., aluminum hydroxide at 30-100 mg/kg/day PO divided with meals), and management of metabolic acidosis with sodium bicarbonate or potassium citrate. Erythropoietin therapy may be considered for anemia (e.g., darbepoetin alfa at 1-2 mcg/kg SC once weekly, titrated to hematocrit). Hypertension should be treated with amlodipine (0.1-0.25 mg/kg PO q24h) or enalapril (0.5 mg/kg PO q12-24h). Gastrointestinal signs can be managed with antiemetics (e.g., maropitant at 1 mg/kg SC q24h) and gastric protectants (e.g., omeprazole at 0.5-1 mg/kg PO q24h). In cases of unilateral dysplasia with a nonfunctional kidney, nephrectomy may be considered if the contralateral kidney is normal, but this is rarely performed. Renal transplantation is an option in select cases but is not widely available.

The prognosis for renal dysplasia is generally poor to guarded, especially when bilateral and diagnosed at a young age. The rate of progression varies; some animals may live for months to years with appropriate management, while others progress rapidly to end-stage renal failure. Negative prognostic indicators include severe azotemia at diagnosis, marked proteinuria, systemic hypertension, and poor response to therapy. Unilateral disease carries a better prognosis if the contralateral kidney is healthy. Median survival times in dogs with juvenile CKD have been reported to range from 6 to 24 months, depending on the severity and management. Early diagnosis and aggressive management may slow progression.

Follow-up should be scheduled at regular intervals, typically every 1-3 months initially, then every 3-6 months once stable. At each visit, body weight, blood pressure, and body condition score should be assessed. Serial monitoring of serum creatinine, BUN, phosphorus, calcium, electrolytes, and SDMA is recommended. Urinalysis and UPC should be repeated to monitor proteinuria. Complete blood count should be checked periodically to assess anemia. Imaging (ultrasound) may be repeated every 6-12 months to monitor kidney size and architecture. Dose adjustments of medications (e.g., phosphate binders, antihypertensives) should be based on laboratory results. Owners should be educated on signs of uremic crisis and the importance of maintaining hydration.

Pearls: 1) Always consider renal dysplasia in a young dog or cat with chronic kidney disease, especially in predisposed breeds. 2) A renal biopsy is the only definitive diagnostic test; do not rely solely on imaging. 3) Early intervention with a renal diet and phosphate binders can slow progression. 4) Monitor blood pressure regularly, as hypertension is common and can worsen renal damage. 5) SDMA is a more sensitive marker than creatinine for early detection of decreased renal function. Pitfalls: 1) Do not mistake renal dysplasia for acute kidney injury; a thorough history and chronicity of signs are key. 2) Avoid overuse of nephrotoxic drugs (e.g., NSAIDs) in these patients. 3) Do not delay biopsy if the diagnosis is uncertain, as early confirmation allows for appropriate genetic counseling and management. 4) Be cautious with fluid therapy in chronic cases to avoid volume overload. 5) Do not forget to screen for concurrent urinary tract infections.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: 1) Phosphate binders: Aluminum hydroxide (30-100 mg/kg/day PO divided with meals) or calcium carbonate (90 mg/kg/day PO divided with meals). 2) ACE inhibitors: Enalapril (0.5 mg/kg PO q12-24h) or benazepril (0.25-0.5 mg/kg PO q24h) for proteinuria and hypertension. 3) Antihypertensive: Amlodipine (0.1-0.25 mg/kg PO q24h) if ACE inhibitor alone is insufficient. 4) Erythropoietin: Darbepoetin alfa (1-2 mcg/kg SC once weekly) or epoetin alfa (100-150 IU/kg SC three times weekly) to target hematocrit of 30-35%. 5) Antiemetics: Maropitant (1 mg/kg SC q24h) or ondansetron (0.5-1 mg/kg IV q12h). 6) Gastric protectants: Omeprazole (0.5-1 mg/kg PO q24h) or famotidine (0.5 mg/kg PO q12h). 7) Potassium supplementation: Potassium gluconate (2-4 mEq/100 kcal PO q12h) if hypokalemia. 8) Sodium bicarbonate (8-12 mg/kg PO q8-12h) to correct acidosis. 9) Omega-3 fatty acids (eicosapentaenoic acid/docosahexaenoic acid at 40-100 mg/kg/day PO) as adjunctive therapy. 10) In cases of urinary tract infection, appropriate antibiotics based on culture and sensitivity, with dose adjustment for renal function.

Renal dysplasia is well-documented in veterinary literature. A landmark study by Picut and Lewis (1987) described the histopathological features of renal dysplasia in dogs. Breed-specific studies have identified hereditary patterns in Shih Tzus and Golden Retrievers. The International Renal Interest Society (IRIS) provides guidelines for staging and management of chronic kidney disease, which are applicable to renal dysplasia. A study by Vaden et al. (2009) evaluated the use of benazepril in dogs with CKD, showing renoprotective effects. The use of SDMA as a biomarker has been validated in multiple studies, including those by Nabity et al. (2015). Consensus recommendations from ACVIM and ECVIM emphasize the importance of early diagnosis and management of proteinuria and hypertension. There is limited literature specifically on renal dysplasia, but extrapolation from CKD studies is appropriate. Genetic testing is emerging for some breeds, and future research may focus on gene therapy.